Immunoadjuvants in Cancer Immunotherapy DOI

Mamta N. Talati,

Neeraj Kumar Chouhan,

Mani Sharma

и другие.

Advances in medical diagnosis, treatment, and care (AMDTC) book series, Год журнала: 2024, Номер unknown, С. 311 - 350

Опубликована: Авг. 28, 2024

Immunoadjuvants are crucial components of cancer immunotherapy that enhance immune responses against tumors. This chapter explores the underlying mechanisms and clinical uses immunoadjuvants in immunotherapy. Toll-like receptor agonists STING two types activate cells promote anti-tumor immunity. Cytokine-based have potential toxicity off-target effects, but nanotechnology enables precision delivery to minimize these issues. Personalized approaches, biomarker discovery, predictive modeling important for optimizing treatment responses. Overall, essential tools generating strong long-lasting In conclusion, critical immunotherapy, playing a vital role boosting durable

Язык: Английский

Vaccination and personalized cancer vaccines focusing on common cancers in women: a narrative review DOI
Seyed Sadeq Mousavi Ghahfarrokhi, Pegah Karimi,

Fateme-Sadat Mahdigholi

и другие.

Pathology - Research and Practice, Год журнала: 2025, Номер 270, С. 155983 - 155983

Опубликована: Апрель 18, 2025

Язык: Английский

Процитировано

1

Lipoplexes’ Structure, Preparation, and Role in Managing Different Diseases DOI
Sally A. El‐Zahaby, Lovepreet Kaur, Ankur Sharma

и другие.

AAPS PharmSciTech, Год журнала: 2024, Номер 25(5)

Опубликована: Июнь 7, 2024

Язык: Английский

Процитировано

5

Redefining Hepatocellular Carcinoma Treatment: Nanotechnology Meets Tumor Immune Microenvironment DOI
Chen Mi, Sai Liu, Zhida Chen

и другие.

Journal of drug targeting, Год журнала: 2025, Номер unknown, С. 1 - 47

Опубликована: Март 13, 2025

Hepatocellular carcinoma (HCC) is one of the most lethal malignancies worldwide, characterized by its complex pathogenesis and poor therapeutic outcomes. Despite recent advances in targeted molecular therapies, immune checkpoint inhibitors (ICIs), radiotherapy, conventional chemotherapy, five-year survival rate for this neoplasm remains dismally low. The progress nanotechnology has revolutionized cancer treatment years. These provide unprecedented opportunities to overcome current limitations different modalities. This review provides a comprehensive analysis how interfaces with tumor microenvironment (TIME) HCC can present new frontier interventions HCC. We critically overview latest developments nanoparticle-based delivery systems various drugs also other antitumor agents like thermal therapy radiotherapy. highlight unique ability nanoparticles modulate immunosuppressive (TME) enhance efficacy. Furthermore, we analyze emerging strategies that exploit nanoformulations biological barriers drug bioavailability treatment.

Язык: Английский

Процитировано

0

Advancements and challenges in personalized neoantigen-based cancer vaccines DOI Creative Commons

Parminder Singh,

Mahalaqua Nazli Khatib,

R Roopashree

и другие.

Oncology Reviews, Год журнала: 2025, Номер 19

Опубликована: Март 14, 2025

Advancements in personalized neoantigen-based cancer vaccines are ushering a new era oncology, targeting unique genetic alterations within tumors to enhance treatment precision and efficacy. Neoantigens, specific cells absent normal tissues, at the heart of these vaccines, promising direct immune system specifically against tumor, thereby maximizing therapeutic efficacy while minimizing side effects. The identification neoantigens through genomic proteomic technologies is central developing allowing for precise mapping tumor's mutational landscape. Despite advancements, accurately predicting which will elicit strong responses remains challenging due tumor variability complexity interactions. This necessitates further refinement bioinformatics tools predictive models. Moreover, heavily depends on innovative delivery methods that neoantigen presentation system. Techniques like encapsulating lipid nanoparticles using viral vectors critical improving vaccine stability delivery. Additionally, contribute towards achieving Sustainable Development Goal 3.8, promoting universal health coverage by advancing access safe effective treatments. review delves into potential transform treatment, examining both revolutionary advancements ongoing challenges they face.

Язык: Английский

Процитировано

0

Harnessing Histone Deacetylase Inhibitors for Enhanced Cancer Immunotherapy DOI

Fatemeh Hedayat,

Elnaz Faghfuri

European Journal of Pharmacology, Год журнала: 2025, Номер 997, С. 177620 - 177620

Опубликована: Апрель 14, 2025

Язык: Английский

Процитировано

0

Approaches and challenges in cancer immunotherapy pathways DOI Open Access
Μαρία Καπρίτσου

World Journal of Clinical Oncology, Год журнала: 2024, Номер 15(3), С. 378 - 380

Опубликована: Март 22, 2024

Cancer immunotherapy is an effective with critical approaches in the treatment of oncological patients. Whilst numerous research and clinical trials are underway to develop endogenous approaches, it necessary focus on fundamental issues identify barriers basic progress. Addressing these challenges new pathways will require researchers clinicians join forces accelerate understanding complex interactions between cancer immune system resources developing better treatments for

Язык: Английский

Процитировано

0

Intranasal LAG3 antibody infusion induces a rapid antidepressant effect via the hippocampal ERK1/2-BDNF signaling pathway in chronically stressed mice DOI

Yunli Fang,

Hainan Pan,

Hao‐Jie Zhu

и другие.

Neuropharmacology, Год журнала: 2024, Номер 259, С. 110118 - 110118

Опубликована: Авг. 15, 2024

Язык: Английский

Процитировано

0

Immunoadjuvants in Cancer Immunotherapy DOI

Mamta N. Talati,

Neeraj Kumar Chouhan,

Mani Sharma

и другие.

Advances in medical diagnosis, treatment, and care (AMDTC) book series, Год журнала: 2024, Номер unknown, С. 311 - 350

Опубликована: Авг. 28, 2024

Immunoadjuvants are crucial components of cancer immunotherapy that enhance immune responses against tumors. This chapter explores the underlying mechanisms and clinical uses immunoadjuvants in immunotherapy. Toll-like receptor agonists STING two types activate cells promote anti-tumor immunity. Cytokine-based have potential toxicity off-target effects, but nanotechnology enables precision delivery to minimize these issues. Personalized approaches, biomarker discovery, predictive modeling important for optimizing treatment responses. Overall, essential tools generating strong long-lasting In conclusion, critical immunotherapy, playing a vital role boosting durable

Язык: Английский

Процитировано

0